Breed s Hill Capital LLC Increases Stock Position in Stryker Corporation $SYK

Key Points

• Breed's Hill Capital LLC increased its stake in Stryker Corporation by 111.9%, owning 1,322 shares valued at approximately $492,000 as per its recent SEC filing.
• Stryker's shares reported a 2.2% increase in value, currently priced at $389.96, while the company aims for EPS guidance between $13.400 and $13.600 for FY 2025.
• The company declared a quarterly dividend of $0.84 per share, with a dividend yield of 0.9%, to be paid on October 31st to shareholders of record as of September 30th.

Breed s Hill Capital LLC boosted its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 111.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,322 shares of the medical technology company's stock after buying an additional 698 shares during the quarter. Breed s Hill Capital LLC's holdings in Stryker were worth $492,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of SYK. Capital A Wealth Management LLC purchased a new position in Stryker during the fourth quarter worth about $26,000. Goodman Advisory Group LLC purchased a new position in Stryker during the first quarter worth about $32,000. City Holding Co. boosted its stake in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after buying an additional 74 shares during the period. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the first quarter worth about $40,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Stryker during the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Up 2.2%

Shares of NYSE:SYK opened at $389.9640 on Wednesday. The firm's 50 day moving average price is $386.87 and its 200 day moving average price is $379.45. The stock has a market cap of $149.09 billion, a price-to-earnings ratio of 51.65, a price-to-earnings-growth ratio of 2.77 and a beta of 0.91. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm's revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on SYK shares. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a "hold" rating in a research report on Monday, August 4th. Citigroup reissued a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Roth Mkm increased their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research report on Monday, May 5th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and a consensus price target of $430.10.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.20% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.